

Bevacizumab plusXELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.

Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F (2015) Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. *World J Gastroenterol* 21(23), 7281-7288.


[Details](#)



Abstract

To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.

Leibniz-HKI-Autor*innen



Selene Mogavero

[Details](#)

Identifier

doi: 10.3748/wjg.v21.i23.7281

